Dryocrassin ABBA

CAS No. 12777-70-7

Dryocrassin ABBA( —— )

Catalog No. M21799 CAS No. 12777-70-7

Dryocrassin ABBA (Dryocrassin) is a flavonoid natural product derived from Dryopteris crassirhizoma, with antiviral and antibacterial activities.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 488 In Stock
10MG 826 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Dryocrassin ABBA
  • Note
    Research use only, not for human use.
  • Brief Description
    Dryocrassin ABBA (Dryocrassin) is a flavonoid natural product derived from Dryopteris crassirhizoma, with antiviral and antibacterial activities.
  • Description
    Dryocrassin ABBA (Dryocrassin) is a flavonoid natural product derived from Dryopteris crassirhizoma, with antiviral and antibacterial activities. Dryocrassin ABBA exhibits antiviral activity against H5N1 avian influenza virus. Dryocrassin ABBA inhibits the coagulase activity of Staphylococcus aureus vWbp. Dryocrassin ABBA suppresses immunostimulatory function of dendritic cells and prolongs skin allograft survival.
  • In Vitro
    Dryocrassin ABBA (Dryocrassin) inhibits the activity of S. aureus SrtA (sortase A) with an IC50 of 24.17 μM.
  • In Vivo
    Dryocrassin ABBA (Dryocrassin) (0-33 mg/kg; i.g.; daily, 7 days from day 2 to day 8) exerts a significant dose-dependent antiviral effect in mice.Dryocrassin ABBA (100 mg/kg; s.c.; every 12 h for 96 h) can reduce infection and prevent mice from contracting S. aureus pneumonia. Animal Model:SPF BALB/C female mice inoculated intra-nasally with 104.5ELD50 H5N1 viruses in 100 μl salineDosage:33, 18, and 12.5 mg/kg Administration:Oral gavage, daily, 7 days from day 2 to day 8 Result:Significantly reduced mortality, prolonged survival rate, and improved survival time throughout the infection period. Increased body weight and reduced lung lesions and virus loads. Significantly increased MCP-1 and IL-10 while significantly decreased IL-12, IL-6, IFN-γ and TNF-α.Animal Model:Eight-week-old C57BL/6J mice infected with 30 μL of S. aureus Newman (2 × 108 CFU/10 μL) by intranasal administrationDosage:100 mg/kg Administration:Subcutaneous injection, every 12 h for 96 h Result:Resulted a significant increase in survival.
  • Synonyms
    ——
  • Pathway
    Microbiology/Virology
  • Target
    Influenza Virus
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    12777-70-7
  • Formula Weight
    820.83
  • Molecular Formula
    C??H??O??
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 16.67 mg/mL (20.31 mM)
  • SMILES
    OC1=C(C(O)=C(C(CCC)=O)C(O)=C1CC(C(C(C(C)=O)=C(O)C2(C)C)=O)=C2O)CC(C(O)=C(C(CCC)=O)C(O)=C3CC(C(C(C(C)=O)=C(O)C4(C)C)=O)=C4O)=C3O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Ou C, et al. Dryocrassin ABBA, a novel active substance for use against amantadine-resistant H5N1 avian influenza virus. Front Microbiol. 2015 Jun 16;6:592. 2. Zhang B, et al. Molecular Mechanism of the Flavonoid Natural Product Dryocrassin ABBA against Staphylococcus aureus Sortase A. Molecules. 2016 Oct 26;21(11). 3. Li B, et al. An Inhibitory Effect of Dryocrassin ABBA on Staphylococcus aureus vWbp That Protects Mice From Pneumonia. Front Microbiol. 2019 Jan 23;10:7.
molnova catalog
related products
  • CBS1117

    CBS1117 is an inhibitor virus entry inhibitor(IC50 of 70 nM for influenza A virus), A/Puerto Rico/8/34 (H1N1).?It interferes with the hemagglutinin (HA)-mediated fusion process.CBS1117 which has a 50% inhibitory concentration of 70 nM and a selectivity index of ~4000 against A/Puerto Rico/8/34 (H1N1) infection in human lung epithelial cell line (A549).

  • Oseltamivir phosphat...

    A competitive inhibitor of influenza neuraminidase that prevents new viral particles from being released.

  • NS1-IN-1

    NS1-IN-1 is a potent NS1 inhibitor.NS1-IN-1 displays antiviral activity by inhibiting mTORC1 activity in a TSC1-TSC2-dependent manner.